Ozempic, Weight, & Identity—A Guide for Mental Health Providers

The AMHTI and AASECT CE certificates are separate. We do not charge you for CE certificates. However, because of the administrative costs that we incur, please request only certificates you will use.

I request a CE certificate from AMHTI

I request a CE certificate from AASECT

1. Today’s ultra-processed food:*

a. is not controversial

b. undermines our ability to feel full

c. offers significant nutrition lessons for children

d. none of the above

2. GLP-1 agonists:*

a. affect areas of the brain that process hunger & satiety

b. increase how full someone feels during & after eating

c. slows stomach emptying, so people feel full longer

d. all of the above

3. What percentage of people who start a GLP-1 agonist are still taking it one year later?*

a. 10%

b. 50%

c. 90%

d. We don’t yet have enough data to answer this question.

4. Which is not a common feature of GLP-1 use?*

a. a reduction in “food noise”

b. a reduction in alcohol, tobacco, and other non-food cravings

c. food loses its attractive taste and smell

d. eating becomes less of a social event

5. According to the speaker, many GLP-1 users lose some of their narrative of powerlessness.*

a. True

b. False

6. As long as the drug is prescribed by a physician and sold by a licensed pharmacy, there are generally very few unexpected consequences from using a GLP-1 agonist.*

a. True

b. False

7. A couple’s system can be disrupted if only one partner uses a GLP-1 agonist:*

a. True, because their life experiences can diverge significantly

b. True, because only a person with mental health problems would take a GLP-1 agonist

c. False, because losing weight is not a significant event for most overweight people

d. False, because most couples love each other enough to keep weight loss in perspective

8. Regarding the use of GLP-1 agonists, the therapist’s role is to*

a. urge an overweight patient to take the drug

b. check with a patient’s spouse before encouraging or discouraging a patient from starting use

c. supervise what dose a patient should take

d. help patients deal with any associated guilt, shame, or secrecy

9. According to the speaker, most physicians don’t discuss the psychological or relational issues involved with GLP-1 use.*

a. True

b. False

10. We know the following about GLP-1 agonists:*

a. a user should plan to use this drug lifelong.

b. if a user loses weight easily, they can usually handle the resulting non-weight issues easily, too.

c. they are currently inexpensive

d. none of the above

Name*

First

Last

Address*

City*

State*

Zip*

License #*

Phone*

Email address*

CEU certificates will be sent within 21 days of receiving this form.

Ozempic, Weight, & Identity—
A Guide for Mental Health Providers

Please complete and submit this questionnaire. Once we receive your answers we will process your CEUs and email your certificate.

<< Back to deliverables

Ozempic, Weight, & Identity— A Guide for Mental Health Providers

Please complete and submit this questionnaire. Once we receive your answers we will process your CEUs and email your certificate.

<< Back to deliverables

Login

Register

Ozempic, Weight, & Identity—
A Guide for Mental Health Providers